Literature DB >> 2548109

Efflux of rubidium in rat cortical synaptosomes is blocked by sigma and dextromethorphan binding site ligands.

E J Fletcher1, C Drew, D Lodge, C T O'Shaughnessy.   

Abstract

Large concentrations of potassium were used to stimulate the release of rubidium-86 from preloaded cortical synaptosomes, so that the pharmacological sensitivity of this efflux could be examined. Potassium channel blockers, 4-aminopyridine and tetraethylammonium, inhibited the evoked release of rubidium. Sigma ligands, e.g. pentazocine, cyclazocine, rimcazole, 1,3-di(2-tolyl)guanidine (DTG) and haloperidol, as well as the antitussives, carbetapentane, caramiphen and dextromethorphan, significantly reduced potassium-stimulated efflux of rubidium. By contrast, 3-hydroxyphenyl-propylpiperidine (3-PPP), 5-methyl-10,11-dihydro-5H-dibenzo(a,d)-cyclohepten-5,10-imine (MK-801), phencyclidine (PCP), ketamine and D-2-amino-5-phosphonovalerate (D-AP5) were all inactive. This suggests that inhibition of potassium-stimulated efflux of rubidium is correlated with activity at the sigma and/or dextromethorphan binding sites rather than at the N-methyl-D-aspartate (NMDA)/PCP receptor-channel complex.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2548109     DOI: 10.1016/0028-3908(89)90148-2

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  3 in total

1.  Focal stimulation of specific pathways in the rat hippocampus causes a reduction in radioligand binding to the haloperidol-sensitive sigma receptor.

Authors:  M A Connor; C Chavkin
Journal:  Exp Brain Res       Date:  1991       Impact factor: 1.972

Review 2.  Ketamine and phencyclidine: the good, the bad and the unexpected.

Authors:  D Lodge; M S Mercier
Journal:  Br J Pharmacol       Date:  2015-07-28       Impact factor: 8.739

3.  Selective reduction of N-methyl-D-aspartate-evoked responses by 1,3-di(2-tolyl)guanidine in mouse and rat cultured hippocampal pyramidal neurones.

Authors:  E J Fletcher; J Church; K Abdel-Hamid; J F MacDonald
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.